LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that results from the open-label, single-agent Phase 2 ENABLE proof-of-concept clinical trial demonstrate bafetinib’s clinical activity and preliminary safety in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). The results were presented by Tapan Kadia, M.D., Department of Leukemia at the University of Texas, M.D. Anderson Cancer Center, in a poster session at the 2011 American Society of Hematology (ASH®) Annual Meeting. CytRx also announced that the ENABLE abstract has been selected for inclusion in the Highlights of ASH® program for presentation in 2012 in ASH meetings in Austin, Orlando, Atlanta, Las Vegas, New York and San Francisco.
